Microsurgical Head and Neck Reconstruction Is Cost-Effective

Share this content:
Microsurgical Head and Neck Reconstruction Is Cost-Effective
Microsurgical Head and Neck Reconstruction Is Cost-Effective

THURSDAY, Dec. 15, 2016 (HealthDay News) -- For patients with squamous cell carcinoma (SCC), microsurgical head and neck reconstruction is cost-effective compared with locoregional flaps, according to a study published online Nov. 29 in Head & Neck.

Lin Lin Gao, M.D., from the University of Pennsylvania Health System in Philadelphia, and colleagues examined the cost-effectiveness of free flap reconstruction for head and neck defects after oncologic resection for SCC. A Markov model was developed for the cost, quality of life, survival, and incremental cost-effectiveness of reconstruction with free tissue transfer versus locoregional flaps.

The researchers found that, compared with pedicled flap, free flap reconstruction was more costly, but associated with greater quality of life, with no survival benefit. Using a definition of cost-effectiveness of <$50,000 per quality-adjusted life-year (QALY), the incremental cost-effectiveness for head and neck free flap reconstruction was below the threshold, and therefore considered cost-effective. For patients with lower-stage cancers, reconstruction was more cost-effective: $4,643, $8,226, $17,269, and $23,324 per QALY for stage I, II, III, and IV SCC, respectively. Cost-effectiveness remained <$50,000 in sensitivity analysis for all SCC stages for all variables except QALY after locoregional reconstruction without complications.

"This finding supports the current practice of free flap head and neck reconstruction," the authors write. "Screening and early detection are important to optimize costs."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Belimumab Aids Anti-dsDNA, Hypocomplementemic Lupus

Belimumab Aids Anti-dsDNA&#43;, Hypocomplementemic Lupus

More SLE Responder Index responders at week 52 in the belimumab group versus the placebo group

Too Few Adults Taking Epilepsy Meds Have Seizure Control

Too Few Adults Taking Epilepsy Meds Have Seizure ...

Ninety percent of those with active epilepsy take meds; 44 percent of those report seizure control

Pediatric Exposures to Liquid Nicotine Down From 2015 to 2016

Pediatric Exposures to Liquid Nicotine Down From 2015 ...

Still poses serious risk to children; decrease likely in part to law requiring child-resistant packaging

is free, fast, and customized just for you!

Already a member?

Sign In Now »